Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dose-Intensive Chemotherapy Combined With Monoclonal Antibody Therapy and Targeted Radioimmunotherapy for Untreated Patients With High-Risk B-Cell Non-Hodgkin's Lymphoma

NCT00577629 is registered in ClinicalTrials.gov with Duke University as lead sponsor.

NCT NCT00577629
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00577629 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dose-Intensive Chemotherapy Combined With Monoclonal Antibody Therapy and Targeted Radioimmunotherapy for Untreated Patients With High-Risk B-Cell Non-Hodgkin's Lymphoma
Lead sponsor
Duke University
Phase
Phase 2
Overall status
Completed
Start date
June 18, 2005
Completion date
November 3, 2016
Enrollment
39 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, b-cell